Figure 3
Expression levels of Grp94, Grp75 and calreticulin in patients' biopsies. (a) Representative western blots of biopsies from Group 0 (S3), Group I (P1, P2, P12, P13), Group II (P20), and Group III patients (P25) stained for Grp94, Grp75, calreticulin (CRT) and actin. The percentage of regenerating fibers (% reg) is indicated above each patient lane. (b) Histograms showing mean and standard error of the mean (SEM) for the normalized Grp75 amount detected in Groups 0, I, II and III (n = 7, 14, 7 and 8, respectively). *Significant difference versus Groups 0 and III (P = 0.01, analysis of variance (ANOVA)). (c) Histograms show mean and SEM of normalized Grp75 amount compared after redistribution of Group I and Group II patients into two new groups based on grading of class I major histocompatibility complex antigen (MHC-I) sarcolemmal immunostaining (see Table 1; n = 11 for MHC-I grade ++ group, 10 for MHC-I grade + group). *Significant difference versus Groups 0 and III (P < 0.005, ANOVA). (d) Histograms showing mean and SEM of normalized calreticulin amount detected in Groups 0, I, II and III (n = 6, 14, 7 and 7, respectively). *Significant difference versus Groups 0 and III (P < 0.01, ANOVA). (e) Histograms showing mean and SEM of normalized calreticulin amount compared after redistribution of Group I and Group II patients, as described for (c). *Significant difference versus all of the groups (P < 0.01, ANOVA).